MTOR and congenital rubella syndrome: In fact, mTOR inhibitors are widely applied in different solid cancers due to their anti-tumor activity, combined with a TCB that targets solid tumors, which seems to be a way to prevent the occurrence of CRS while retaining its efficacy [74, 75].